Phase II study of combination therapy of cisplatin suspension in lipiodol and 5-fluorouracil hepatic arterial infusion for advanced HCC
Phase 2
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000002073
- Lead Sponsor
- Division of Gastroenterology,Kurume University School of Medicine
- Brief Summary
52 cases PFS=8.5 months MST=27 months Tumor Response response rate=75%
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.previous chemotherapy or TAE 2.Previous operation or RFA or PEIT within one year 3.Extrahepatic metastasis or nodes metastasis 4.Concurrent infections(without hepatitis virus) 5.Active double cancers 6.Medical history of severe hypersensitivity. 7.Pregnant,lacting women or women with suspected pregnancy. 8.Inappropriate patients for this study judged by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progrssion free survival
- Secondary Outcome Measures
Name Time Method Overall survival response evaluation complicasion
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cisplatin-lipiodol and 5-FU synergy in advanced hepatocellular carcinoma?
How does cisplatin-lipiodol/5-FU hepatic arterial infusion compare to sorafenib in advanced HCC outcomes?
Which biomarkers correlate with 75% tumor response rate in JPRN-UMIN000002073 HCC combination therapy?
What are the dose-limiting toxicities of cisplatin-lipiodol and 5-FU hepatic arterial infusion in HCC patients?
Are there alternative platinum-based hepatic arterial infusion regimens for advanced HCC with improved MST/PFS profiles?